New Drug Approvals: April 2003

Date of Approval: April 4, 2003

Company: Aventis Pharmaceuticals, Inc

Treatment for Deep Vein Thrombosis -- Prophylaxis

Iprivask is a specific inhibitor of human thrombin indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery.

Date of Approval: April 4, 2003

Company: LG Life Sciences, Ltd

Treatment for Bacterial Infection

Factive is a synthetic broad-spectrum antibacterial agent related to the fluoroquinolone class of antibiotics. Factive is indicated for the treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis.

Company: Alcon

Treatment for Bacterial Conjunctivitis

Date of Approval: April 24, 2003

Company: Genzyme Corp

Treatment for Fabry Disease

Fabrazyme is a recombinant form of human alpha-galactosidase A, administered intravenously for the treatment of Fabry Disease.

Date of Approval: April 30, 2003

Company: Biomarin Pharmaceutical

Aldurazyme is recombinant human alpha-L-iduronidaseis indicated for the treatment of mucopolysaccharidosis I (MPS I).